Asthma and Therapeutics: Recombinant Therapies in Asthma by Donald W Cockcroft
34
Abstract
Numerous recombinant therapies are being inves-
tigated for the treatment of asthma. This report
reviews the current status of several of these
novel agents. Anti–immunoglobulin (Ig)E (omal-
izumab, Xolair) markedly inhibits all aspects of the
allergen challenge in subjects who have reduction
of free serum IgE to undetectable levels. Several
clinical studies in atopic asthma have demon-
strated benefit by improved symptoms and lung
function and a reduction in corticosteroid require-
ments. Early use in atopic asthmatics may be
even more effective. Several approaches target
interleukin (IL)-4. Soluble IL-4 receptor has been
shown to effectively replace inhaled corticosteroid;
further studies are under way. Recombinant anti-
IL-5 and recombinant IL-12 inhibit blood and spu-
tum eosinophils and allergen-induced eosinophilia
without any effect on airway responsiveness, aller-
gen-induced airway responses, or allergen-induced
airway hyperresponsiveness. Efalizumab, a recom-
binant antibody that inhibits lymphocyte trafficking,
is effective in psoriasis. A bronchoprovocation
study showed a reduction in allergen-induced late
asthmatic response and allergen-induced
eosinophilia, which suggests that it should be
effective in clinical asthma. These exciting novel
therapies provide not only promise of new thera-
pies for asthma but also valuable tools for inves-
tigation of asthma mechanisms.
History
As previously reviewed,1 pharmacotherapy for
asthma has changed dramatically in the past 100
years. At the turn of the century, therapy for
acute asthma included mainly narcotics (eg,
heroin, morphine) and sedatives (chloral hydrate),
agents now considered contraindicated in acute
asthma. Inhalants were also advocated for acute
asthma, including amyl nitrate, ether, turpentine,
ammonia, stramonium smoke, and even tobacco!
The only pharmaceutical acting directly on the
airways was atropine. Epinephrine, a nonselec-
tive  and  agonist, identified early in the 1900s
and synthesized shortly thereafter, rapidly became
the standard therapy for acute asthma adminis-
tered subcutaneously at the rate of a minim a
minute. Ephedrine, an old nonselective  and 
agonist extracted from a Chinese herb, ma huang,
was not widely used until well into the twenti-
eth century, when it was usually combined with
theophylline and barbiturates. Isoproterenol, a
selective  (mixed 1-2) agonist, proved to be
an effective bronchodilator2 and was used by
inhalation (nebulization), as was racemic epi-
nephrine. The introduction of the pressurized
metered-dose inhaler (MDI) about 40 years ago
revolutionized the management of asthma. Epi-
nephrine and isoproterenol soon became avail-
able in an MDI, the latter most widely prescribed.
Modifications to sympathomimetics resulted in
increasingly long-acting increasingly selective 2
agonists, the most widely prescribed of which was
salbutamol, introduced in 1967. Further modifi-
cations have resulted in the ultra–long-acting
inhaled 2 agonists salmeterol and formoterol.
Anticholinergics also have a long history of use
in the Far East; atropine-containing tobaccos
made from Datura stramonium were used for
thousands of years in India. This remarkable
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remedy was brought from India to the United
Kingdom about 200 years ago. Atropine has been
available for over 150 years and was mentioned
in Osler’s textbook 100 years ago; however,
atropine seems never to have been very widely
used for asthma.3 In contrast, for the first half of
the twentieth century, many different brands of
asthma cigarettes and asthma burning powders
were available for outpatient management of
asthma. The development of topically active
medium- and long-acting antimuscarinic agents
(ipratropium and tiatropium, respectively) have
resulted in useful pharmacologic therapy that is
more valuable in chronic obstructive pulmonary
disease than in asthma. Theophylline is a com-
pound extracted from tea, another herbal remedy
used for millennia as a stimulant in Asia. Theo-
phylline first became widely available as a phar-
maceutical in the form of the ethylene diamine
salt known as aminophylline. It was initially
used as a stimulant and diuretic but later was used
intravenously and rectally as a bronchodilator.
Oral preparations became available a little over
50 years ago and were often used alone or in com-
bination with ephedrine and barbiturates. Yet
another herbal remedy, khellin, extracted from
Ammi visnaga, was a widely used Middle East-
ern antispasmodic. The cromones sodium cro-
moglycate and nedocromil were modifications of
this herbal remedy. Corticosteroids, the current
cornerstone of asthma therapy, arrived on the
scene relatively recently, having been available
for a little over 50 years. Topically active corti-
costeroids have been available for inhalation
therapy of asthma for almost 30 years now.
The five main classes of asthma drugs up to
the late 1990s were all developed and modified
from plant (ephedrine, atropine, theophylline,
khellin) or animal (epinephrine, cortisone) sources.
In the late 1990s, the first designer drugs for the
management of asthma appeared in the form of
various leukotriene modifiers, including lipoxy-
genase inhibitors and the more successful oral
leukotriene receptor antagonists, such as mon-
telukast. The currently available pharmaceutical
armamentarium for the management of asthma is
actually quite good. Appropriate and particularly
early use of anti-inflammatory strategies (in addi-
tion to education and environmental control) is
stressed by clinical practice guidelines.4
Nevertheless, numerous new pharmaceutical
developments continue to be designed for asthma
treatment, as summarized in a recent review.5 Sev-
eral of these pharmacotherapies have been devel-
oped using genetic recombinant technologies,
including recombinant antibodies, interleukins
(ILs), IL receptors, and IL receptor blockers. This
review article covers several of these recombinant
therapies, which involve immunoglobulin (Ig)E,
IL-4, IL-5, IL-12, and lymphocytes. These excit-
ing new agents provide potentially new thera-
peutic options for asthma and valuable tools for
investigation of mechanisms in asthma.
Immunoglobulin E
Background
IgE antibody was identified as the cause of atopic
sensitization and atopic allergic reactions about 35
years ago.6 In the last 25 years, laboratory inves-
tigations identifying allergen inhalation as a cause
of both airway hyperresponsiveness7 and airway
inflammation8 have allowed the reclassification of
allergens as important inducers of asthma.9 This
information has been supplemented by numerous
epidemiologic studies, which now confirm that
atopy is the most important single risk factor for
the development of asthma,10–12 and, thus, that
IgE-mediated allergic airway inflammation is the
most important cause of asthma. It is therefore log-
ical to direct therapeutic strategies towards this end.
Indeed, environmental control, where possible,
is one of the cornerstones of asthma therapy and,
for a single and completely avoidable allergen or
sensitizer, such as in the occupational setting, can,
in fact, be curative.13 Sodium cromoglycate prob-
ably has its major effect in chronic asthma man-
agement as a prophylactically anti-inflammatory
asthma therapy by preventing all aspects of the
allergen-induced asthmatic response.14 A number
of approaches are available to address IgE and its
interaction with effector cells. At this point, the
most promising therapy, and that nearest market-
ing, is a monoclonal anti-IgE antibody, omal-
izumab (Xolair).
Anti-IgE Development
The development of anti-IgE antibodies is briefly
outlined as a general background to the prepara-
tion of such agents. Initially, a series of clonal
murine IgG antibodies directed against human
IgE were developed. The clone demonstrating
the ideal characteristics, namely reacting with or
at least hiding the Fc component of the IgE mol-
ecule (ie, that area of the molecule that binds
with the Fc receptor on mast cells), was selected.
The majority (about 95%) of this murine IgG
antibody was then replaced with human IgG,
leaving only a small amount of the antibody-spe-
cific variable area of the antibody as murine in ori-
gin.15 The twenty-fifth antibody in the series,
recombinant humanized murine monoclonal anti-
body E25 (rhuMAb-E25 [E25 for short], omal-
izumab, Xolair) had the desired characteristics,
which included good tolerability, a reduction in
free serum IgE to undetectable levels, inhibition
of allergic reactions, a lack of mast cell degran-
ulation (unlike polyclonal anti-IgE, which serves
as a model to mimic allergic reactions), and a lack
of immunogenicity (the latter the result of the
95% humanization).16 Additionally, Fc recep-
tors are up-regulated in the presence of high
serum IgE and down-regulated in the presence of
low serum IgE17; therefore, omalizumab results
in reduction in Fc receptors, which may lead to
reduced IgE synthesis16; this may allow at least
the possibility of being able to lower the effective
dose of omalizumab.
Laboratory Studies
The allergen challenge model is a useful method
to study asthma pharmaceutical agents.18 This
would be particularly true for an agent designed
to prevent IgE-mediated airway allergic responses.
Omalizumab administered intravenously at a stan-
dard dose of 0.5 mg/kg/wk proved to be very
effective in inhibition of the early asthmatic
response (EAR) and the late asthmatic response
(LAR).19,20 Fahy and colleagues demonstrated a
63% reduction of the allergen-induced LAR after
10 weeks of intravenous therapy of omalizumab
0.5 mg/kg/wk.19 The results are even more impres-
sive when one takes into account that subjects
receiving omalizumab actually received approx-
imately twice as much allergen post-treatment as
did those who received placebo. The second aller-
gen challenge study involved an EAR model with
the EAR reported as the allergen PC15. The advan-
tages of this model are that it allows study in a
larger number of subjects and studies in subjects
who are less severe and consequently more stable,
and it allows better quantitation of therapeutic
effect, particularly where the therapeutic effect is
large. The disadvantage of this model is the inabil-
ity to study the more important late consequences,
including the LAR, allergen-induced increase in
airway responsiveness, and allergen-induced air-
way inflammation. We demonstrated a marked
and early shift of the allergen PC15 as early as 4
weeks.20 After 10 weeks of treatment with 1 mg/kg
for 2 weeks (the same total dose used in the Fahy
and colleagues’ study19 but administered every 2
weeks), there was a 6.5-fold improvement in aller-
gen PC15.
20 In both allergen challenge studies, the
drug was well tolerated, with the only important
event being a single episode of first-dose urticaria,
which is occasionally seen and does not recur on
repeat exposure. No antiomalizumab antibodies
developed. We observed that those subjects who
were not protected against the antigen challenge
were those in whom free serum IgE was not com-
pletely reduced to undetectable levels. Subse-
quently, studies have dosed E25 based not only on
weight but also on total baseline serum IgE lev-
els.21 A third study investigated nebulized omal-
izumab in high dose (10 mg/d) and moderate dose
(1 mg/d) for 8 weeks. Nebulized omalizumab had
no effect on serum IgE levels and no effect on aller-
gen challenge.21 There was a single case of
antiomalizumab antibodies developing via the
inhaled route.
Clinical Studies
An early clinical study in ragweed allergic rhini-
tis served primarily to underscore the need for ade-
quate omalizumab dosing based on serum IgE.22
The first clinical asthma study examined two
doses, 2.5 g and 5.8 g/kg/ng IgE, adminis-
tered intravenously at two-weekly intervals.23
There was improvement in lung function and
symptoms in the active groups and, after 
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12 weeks, subjects on active therapy were able to
reduce their corticosteroids by a larger amount
than were those on placebo. These results were
interpreted very optimistically. Recently, two
large omalizumab trials of apparently identical
design have been reported.24,25 These parallel
studies have involved more than 500 subjects
receiving omalizumab compared with approxi-
mately the same number on placebo. The active
patients received omalizumab 0.016 mg/kg IgE
(IU/mL) every 4 weeks administered subcuta-
neously with doses administered every 2 or 4
weeks depending on the volume. During the 16-
week steroid-stable phase, these asthmatic sub-
jects, with a mean duration of asthma over 20
years, demonstrated reduced exacerbations,
reduced symptoms, and improved lung function.
In the subsequent corticosteroid reduction phase,
over the next 12 weeks, the subjects on omal-
izumab were able to reduce their inhaled corti-
costeroids by a larger amount than were those on
placebo. In all studies, omalizumab has been well
tolerated, and there have been no instances of
the development of antiomalizumab antibodies in
any subject receiving parenteral omalizumab.
Hypothesis
Omalizumab has demonstrated statistically sig-
nificant and clinically relevant improvement in
allergic asthma in several studies. The marked
success of omalizumab in the bronchoprovocation
studies, however, suggested that omalizumab
might have worked even better.  
There are increasing data to support the view
that early use of anti-inflammatory therapeutic
strategies may improve the natural history of asthma.
It was first shown that the late introduction of cor-
ticosteroids, even in a survival population treated
with 2 agonist alone for the first 2 years of asthma,
did not allow catch-up to those individuals who
started on corticosteroids early.26 This has been
confirmed by other studies.27 This issue related to
early therapy is likely more relevant for prophylactic
anti-inflammatory therapies such as environmen-
tal control, as has been best demonstrated with
occupational asthma in which early environmental
control frequently resulted in a cure, whereas
delayed environmental control, although helpful,
was associated with persistent asthma airway hyper-
responsiveness and airway inflammation.13 The
anti-inflammatory effects of omalizumab should be,
to a large extent (perhaps completely), analogous
to environmental control. One could hypothesize
that omalizumab might be particularly effective,
therefore, when introduced early in subjects with
allergic asthma. This testable hypothesis would
require studies of omalizumab targeting children and
adolescents with recent-onset atopic asthma.
Interleukin-4
Background
IL-4 is regarded as the most important cytokine
underlying the development of the allergic type of
inflammation by a number of mechanisms, includ-
ing IgE production, up-regulation of Fc receptors,
induction of adhesion molecules, and differenti-
ation of lymphocytes towards the T helper 2 (Th2)
phenotype, which favours maintenance of the
allergic type of airway inflammation.28 Thera-
peutic strategies designed to block the effect of IL-
4 should therefore be effective in asthma and other
atopic allergic disorders. Recombinant pharma-
ceutical agents targeting IL-4 include soluble IL-
4 receptor (IL-4R),29 an IL-4/13 receptor blocker,30
and anti–IL-4 antibodies.31 All of these are in var-
ious stages of investigation. Soluble IL-4R, effec-
tive in a murine allergen challenge model,29 has
the most reported data in humans.
Soluble IL-4R
Recombinant soluble IL-4R is a relatively low-mol-
ecular-weight protein representing the extracellu-
lar component of the cell membrane IL-4R. Solu-
ble IL-4R reduces the effect of IL-4 in tissues by
competing with membrane-bound IL-4Rs, thus
reducing the biologic activity of IL-4. There are two
clinical studies in humans in which nebulized IL-
4 was shown to have some effect.32,33 In a prelim-
inary small placebo-controlled study,32 two dif-
ferent doses of nebulized IL-4R (500 and 1,500 g)
were administered in a single dose on day 1. Inhaled
corticosteroids were stopped on day 0, and the
subjects were followed closely. The drug was well
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tolerated; this was primarily a safety study. No
antibodies developed. The nine subjects receiving
the high dose of IL-4 demonstrated stable symp-
toms, quality of life, and lung function compared
with significant deterioration in the eight subjects
receiving placebo and the eight subjects receiving
the low dose. A subsequent double-blind, placebo-
controlled, dose-ranging study was carried out
over 12 weeks assessing weekly nebulized doses
of 750, 1,500 and 3,000 g in approximately 15
subjects each.33 All subjects were demonstrated
to be dependent on inhaled corticosteroids, which
were stopped abruptly at the beginning of the trial.
Once again, efficacy was demonstrated for solu-
ble IL-4R, particularly in the highest-dose group,
who demonstrated less decline in lung function, less
increase in symptoms, and less requirement for res-
cue medications. IL-4R was demonstrated to be
safe, although one subject in this study did develop
non-neutralizing antibodies to IL-4R.33 Much as
was hypothesized for omalizumab, the maximum
benefit from this (or any other anti-IL-4) strategy
should occur with early use.
Interleukin-5
Airway eosinophilia is a ubiquitous feature in
asthma, and eosinophil levels correlate with dis-
ease activity. Airway eosinophilia, along with the
LAR and airway hyperresponsiveness, can be
induced by exposure to allergen.7,8 Eosinophilia,
LARs, and airway hyperresponsiveness are all
inhibited by inhaled corticosteroids.34 Conse-
quently, it has been assumed that airway hyper-
responsiveness and the LAR may somehow be
caused by the eosinophilia or other airway inflam-
matory cells. IL-5 is the major cytokine respon-
sible for the differentiation and production of
eosinophils.35 Consequently, IL-5 has become a
potential target for new asthma therapies.
There is one double-blind, randomized,
placebo-controlled study in which two different
single doses of intravenous humanized anti–IL-
5 antibody (2.5 and 10 mg/kg) were compared
with placebo.36 The eight subjects with asthma in
each group were then followed for 16 weeks.
As expected, there was a marked effect on both
blood and sputum eosinophils. The suppressive
effect was greater and longer lasting for the high
dose. The anti-IL-5 antibody suppressed allergen-
induced eosinophilia in allergen challenges done
9 and 30 days after the dose. There was no effect,
however, on airway responsiveness to histamine,
the allergen-induced EAR, the allergen-induced
LAR, or the allergen-induced increase in airway
responsiveness to histamine. Although this par-
allel study was not adequately powered to detect
small differences in allergen-induced airway
responses, examination of the data confirms that
there was not even a trend for a difference. 
These results have been interpreted as sur-
prising by many. They provide convincing evi-
dence that airway eosinophilia and airway hyper-
responsiveness may not be as closely linked as had
been previously assumed. This is one way in
which these new recombinant therapies have given
us some remarkable and unsuspected insight into
mechanisms. This, of course, raises important
questions as to the relevance of eosinophils in the
pathogenesis of clinical asthma. Further studies
with this novel therapy, if pursued, may provide
valuable answers.
Interleukin-12
IL-12 is a cytokine involved in the Th1-Th2 balance.
IL-12 has been reported to favour the Th1 as opposed
to the Th2 phenotype. IL-12 is effective in animal
allergen challenge models in inhibiting airway
eosinophilia and airway hyperresponsiveness.37
Recombinant IL-12 was administered subcu-
taneously in increasing doses (0.1, 0.25, and 0.5
g/kg) weekly in 19 individuals compared with
placebo in 20 individuals.38 IL-12, like anti-IL-5,
had a profound effect on eosinophils but no effect
on airway responsiveness or the allergen-induced
LAR. There was a marked reduction in blood and
sputum eosinophilia and a reduction in the mag-
nitude of allergen-induced eosinophilia. IL-12
does not appear to have been terribly well toler-
ated because flu-like symptoms were reported in
the majority of individuals.  
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Lymphocytes
Lymphocytes play an important role in the patho-
genesis of allergic inflammation. Efalizumab is
a humanized murine monoclonal antibody
directed against CD11a. This antibody interferes
with lymphocyte integrin 1 and intercellular
adhesion molecule and blocks T-lymphocyte
activation and trafficking.39 Efalizumab is effec-
tive in the treatment of psoriasis.40 Efalizumab
was investigated in the human allergen chal-
lenge model in a double-blind, parallel study
with 2:1 randomization active:placebo and 2:1
randomization dual asthmatic:early asthmatic
responders. After a conditioning dose, seven
weekly doses of 2 mg/kg were administered sub-
cutaneously. Allergen challenges were done
before and 4 and 8 weeks after starting treat-
ment. The allergen-induced EAR was not
affected. There was a reduction in the allergen-
induced LAR expressed as the maximum percent
fall in forced expiratory volume in 1 second 
(p = .09) and the area under the curve (p = .06)
when compared with placebo.41 In a subset of
patients, we did demonstrate a significant (p <
.05) reduction in allergen-induced sputum
eosinophilia.41 There was a significant preva-
lence of flu-like syndromes with early dosing.
Although not severe, this drug was not as well
tolerated as, for example, omalizumab.
The trend towards inhibition of the allergen-
induced LAR and the definite reduction in eosinophils
points to the importance of lymphocytes and the
pathogenesis of the clinically important late allergen-
induced sequelae. This is another example of the value
of these new recombinant medications in further
clarifying mechanisms of allergen-induced asthma.
The potential role of efalizumab in the therapy of
asthma remains to be determined.
Conclusion
Recombinant therapies that inhibit IgE, which
inhibit (IL-4, IL-5) or mimic (IL-12) ILs and
which block lymphocyte trafficking, are currently
being investigated in asthma. Undoubtedly, other
recombinant approaches are in developmental
stages. These exciting new agents hold promise for
the treatment of asthma and provide valuable tools
for the understanding of mechanisms in asthma.
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